• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy.

作者信息

Razvi Yousuf, Judge Daniel P, Martinez-Naharro Ana, Ioannou Adam, Venneri Lucia, Patel Rishi, Gillmore Julian D, Kellman Peter, Edwards Laura, Taubel Jorg, Du Jing, Tamby Jean-François, Castaño Adam, Siddhanti Suresh, Katz Leonid, Fox Jonathan C, Fontana Marianna

机构信息

Division of Medicine, National Amyloidosis Centre, University College London, Royal Free Hospital, United Kingdom (Y.R., A.M.-N., A.I., L.V., R.P., J.D.G., M.F.).

Medical University of South Carolina, Charleston (D.P.J.).

出版信息

Circ Heart Fail. 2024 Dec;17(12):e012135. doi: 10.1161/CIRCHEARTFAILURE.124.012135. Epub 2024 Oct 28.

DOI:10.1161/CIRCHEARTFAILURE.124.012135
PMID:39465243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11643112/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c6d/11643112/d971804e4e55/hhf-17-e012135-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c6d/11643112/d971804e4e55/hhf-17-e012135-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c6d/11643112/d971804e4e55/hhf-17-e012135-g001.jpg

相似文献

1
Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy.阿考酰胺对转甲状腺素蛋白淀粉样心肌病心肌结构和功能的影响：来自ATTRibute-CM心脏磁共振（CMR）子研究的见解
Circ Heart Fail. 2024 Dec;17(12):e012135. doi: 10.1161/CIRCHEARTFAILURE.124.012135. Epub 2024 Oct 28.
2
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.阿考酰胺在转甲状腺素蛋白淀粉样变心肌病中的长期疗效和安全性：ATTRibute-CM试验开放标签扩展的初步报告
Circulation. 2025 Mar 4;151(9):601-611. doi: 10.1161/CIRCULATIONAHA.124.072771. Epub 2024 Nov 18.
3
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.阿考酰胺对转甲状腺素蛋白淀粉样心肌病全因死亡率和心血管住院治疗的疗效
J Am Coll Cardiol. 2025 Mar 18;85(10):1003-1014. doi: 10.1016/j.jacc.2024.11.042.
4
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.阿伐曲泊帕在转甲状腺素蛋白淀粉样心肌病中的疗效和安全性。
N Engl J Med. 2024 Jan 11;390(2):132-142. doi: 10.1056/NEJMoa2305434.
5
Cardiac Magnetic Resonance Guidance for the Pathogenetic Definition of Cardiomyopathies.心肌病发病机制定义的心脏磁共振引导
Curr Cardiol Rep. 2025 Apr 16;27(1):85. doi: 10.1007/s11886-025-02233-8.
6
Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.基于心血管磁共振成像（CMR）的野生型转甲状腺素蛋白淀粉样变心肌病（ATTRwt）患者用塔法米迪治疗的价值。
Clin Res Cardiol. 2023 Mar;112(3):353-362. doi: 10.1007/s00392-022-02035-w. Epub 2022 Jun 6.
7
Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy.塔法米迪对转甲状腺素淀粉样变心肌病心肌功能和 CMR 组织特征的影响。
ESC Heart Fail. 2024 Oct;11(5):2759-2768. doi: 10.1002/ehf2.14815. Epub 2024 May 12.
8
Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter-Defibrillator Therapy.心脏磁共振成像对比经胸超声心动图对因原发性预防植入式心脏复律除颤器治疗评估而转诊的缺血性和非缺血性扩张型心肌病患者的预后益处。
Circ Cardiovasc Imaging. 2016 Oct;9(10). doi: 10.1161/CIRCIMAGING.115.004956.
9
Cardiac magnetic resonance for prophylactic implantable-cardioverter defibrillator therapy international study: prognostic value of cardiac magnetic resonance-derived right ventricular parameters substudy.心脏磁共振用于预防性植入式心脏复律除颤器治疗的国际研究：心脏磁共振衍生右心室参数亚研究的预后价值。
Eur Heart J Cardiovasc Imaging. 2023 Mar 21;24(4):472-482. doi: 10.1093/ehjci/jeac124.
10
CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter-Defibrillator in Non-Ischemic Cardiomyopathy.基于 CMR 的非缺血性心肌病患者心源性猝死风险分层与植入式心脏复律除颤器的应用。
Int J Mol Sci. 2021 Jul 1;22(13):7115. doi: 10.3390/ijms22137115.

引用本文的文献

1
Pharmacological Management of Transthyretin Amyloid Cardiomyopathy: Where We Are and Where We Are Going.转甲状腺素蛋白淀粉样变心肌病的药物治疗：现状与展望
J Clin Med. 2025 May 16;14(10):3481. doi: 10.3390/jcm14103481.
2
A Tale of Two Diseases: Decoding Aortic Stenosis and Cardiac Amyloidosis.两种疾病的故事：解读主动脉瓣狭窄与心脏淀粉样变
J Clin Med. 2025 Apr 12;14(8):2652. doi: 10.3390/jcm14082652.
3
Evaluation of Extracellular Volume and Coronary Artery Disease in Cardiac Amyloidosis Using Photon-Counting CT.使用光子计数CT评估心脏淀粉样变性中的细胞外容积和冠状动脉疾病

本文引用的文献

1
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.阿伐曲泊帕在转甲状腺素蛋白淀粉样心肌病中的疗效和安全性。
N Engl J Med. 2024 Jan 11;390(2):132-142. doi: 10.1056/NEJMoa2305434.
2
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.心脏磁共振成像在轻链淀粉样变中的应用指导治疗。
Eur Heart J. 2022 Dec 1;43(45):4722-4735. doi: 10.1093/eurheartj/ehac363.
3
Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression.用帕替沙那治疗可降低 CMR 衍生细胞外体积，表明心脏淀粉样变得到了逆转。
Invest Radiol. 2025 Oct 1;60(10):698-707. doi: 10.1097/RLI.0000000000001198.
4
Acoramidis: First Approval.阿考拉米德：首次获批。
Drugs. 2025 Jun;85(6):833-837. doi: 10.1007/s40265-025-02159-z. Epub 2025 Apr 4.
5
The Last Decade in Cardiac Amyloidosis: Advances in Understanding Pathophysiology, Diagnosis and Quantification, Prognosis, Treatment Strategies, and Monitoring Response.心脏淀粉样变性的过去十年：在病理生理学理解、诊断与定量、预后、治疗策略及监测反应方面的进展
JACC Cardiovasc Imaging. 2025 Apr;18(4):478-499. doi: 10.1016/j.jcmg.2024.10.011. Epub 2025 Jan 8.
JACC Cardiovasc Imaging. 2021 Jan;14(1):189-199. doi: 10.1016/j.jcmg.2020.07.043. Epub 2020 Oct 28.
4
Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis.转甲状腺素蛋白心脏淀粉样变性的超声心动图表型与预后
Eur Heart J. 2020 Apr 7;41(14):1439-1447. doi: 10.1093/eurheartj/ehz905.
5
Myocardial Contraction Fraction Predicts Cardiovascular Events in Patients With Hypertrophic Cardiomyopathy and Normal Ejection Fraction.心肌收缩分数可预测射血分数正常的肥厚型心肌病患者的心血管事件。
J Card Fail. 2019 Jun;25(6):450-456. doi: 10.1016/j.cardfail.2019.03.016. Epub 2019 Mar 28.